Answer
Zolbetuximab can attach only when its CLDN18.2 target is sufficiently present on tumour cells, so eligibility must be confirmed with a validated tumour test.
Sources for this answer
- Vyloy powder for concentrate for solution for infusion — Current selected SmPCemc · Summary of Product Characteristics
General medicine information. Follow the instructions for your own medicine and speak to a pharmacist or clinician about your individual circumstances.